Jacob Chacko, MD, has joined the Bonti board of directors. Bonti is a privately held, clinical-stage biotechnology company currently developing a new neurotoxin. Dr. Chacko has served as chief financial officer of Ignyta since May 2014. He is succeeding David Ramsay, who has been a board member since 2015 and is making a planned transition to chief financial officer of Bonti.
Prior to Ignyta, Dr. Chacko was an investor at TPG Capital and served on the boards of directors of RentPath and EnvisionRx. He was also an advisor to the audit committee of Par Pharmaceutical and a board observer to IMS Health and Quintiles Transnational.
“It is a pleasure to welcome Jacob as a member of our board of directors,” said Jonathan Lim, MD, chairman and co-founder of Bonti. “His deep experience building, growing and financing organizations will be invaluable as we continue to rapidly advance our clinical-stage pipeline and prepare for the next stage of Bonti’s development.”
